Mabylon AG
Doug Phillips is a Senior Scientist Antibody Discovery at Mabylon AG, with previous experience as a Scientist II at Cell Medica, Delenex Therapeutics AG, and Expert Scientist at Molecular Partners AG. Before that, Doug was a PhD Student at Cambridge Antibody Technology. Doug holds a PhD in Pharmacy from the University of Reading, an MRes in Biological Sciences from The University of Manchester, and a BSc (Hons) in Medical Biochemistry from the University of Glasgow.
This person is not in any teams
Mabylon AG
Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.